PURPOSE: Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members. The present studies were done to determine the effect of combining topotecan and the dual epidermal growth factor receptor/HER2 inhibitor lapatinib in tissue culture, a murine xenograft model, and a phase I clinical trial. EXPERIMENTAL DESIGN: The effects of lapatinib on topotecan accumulation and cytotoxicity in vitro were examined in paired cell lines lacking or expressing Pgp or BCRP. Antiproliferative effects of the combination were assessed in mice bearing HER2+ BT474 breast cancer xenografts. Based on tolerability in this preclinical model, 37 patients with advanced-stage cancers received escalating doses of lapatinib and topotecan in a phase I trial. RESULTS: Lapatinib increased topotecan accumulation in BCRP- or Pgp-expressing cells in vitro, and the combination showed enhanced efficacy in HER2+ BT474 xenografts. In the phase I study, nausea, vomiting, diarrhea, and fatigue were dose limiting. The maximum tolerated doses were 1,250 mg/d lapatinib by mouth for 21 or 28 days with 3.2 mg/m2 topotecan i.v. on days 1, 8, and 15 of 28-day cycles. Pharmacokinetic analyses showed that combined drug administration resulted in decreased topotecan clearance consistent with transporter-mediated interactions. Seventeen (46%) patients had disease stabilization. CONCLUSIONS: The lapatinib/topotecan combination is well tolerated and warrants further study.
PURPOSE:Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members. The present studies were done to determine the effect of combining topotecan and the dual epidermal growth factor receptor/HER2 inhibitor lapatinib in tissue culture, a murine xenograft model, and a phase I clinical trial. EXPERIMENTAL DESIGN: The effects of lapatinib on topotecan accumulation and cytotoxicity in vitro were examined in paired cell lines lacking or expressing Pgp or BCRP. Antiproliferative effects of the combination were assessed in mice bearing HER2+ BT474 breast cancer xenografts. Based on tolerability in this preclinical model, 37 patients with advanced-stage cancers received escalating doses of lapatinib and topotecan in a phase I trial. RESULTS:Lapatinib increased topotecan accumulation in BCRP- or Pgp-expressing cells in vitro, and the combination showed enhanced efficacy in HER2+ BT474 xenografts. In the phase I study, nausea, vomiting, diarrhea, and fatigue were dose limiting. The maximum tolerated doses were 1,250 mg/d lapatinib by mouth for 21 or 28 days with 3.2 mg/m2 topotecan i.v. on days 1, 8, and 15 of 28-day cycles. Pharmacokinetic analyses showed that combined drug administration resulted in decreased topotecan clearance consistent with transporter-mediated interactions. Seventeen (46%) patients had disease stabilization. CONCLUSIONS: The lapatinib/topotecan combination is well tolerated and warrants further study.
Authors: M Brangi; T Litman; M Ciotti; K Nishiyama; G Kohlhagen; C Takimoto; R Robey; Y Pommier; T Fojo; S E Bates Journal: Cancer Res Date: 1999-12-01 Impact factor: 12.701
Authors: Nienke A de Vries; Jin Zhao; Emily Kroon; Tessa Buckle; Jos H Beijnen; Olaf van Tellingen Journal: Clin Cancer Res Date: 2007-11-01 Impact factor: 12.531
Authors: Joseph W Polli; Joan E Humphreys; Kelly A Harmon; Stephen Castellino; Michael J O'Mara; Katie L Olson; Lisa St John-Williams; Kevin M Koch; Cosette J Serabjit-Singh Journal: Drug Metab Dispos Date: 2008-01-23 Impact factor: 3.922
Authors: M Huls; C D A Brown; A S Windass; R Sayer; J J M W van den Heuvel; S Heemskerk; F G M Russel; R Masereeuw Journal: Kidney Int Date: 2007-10-31 Impact factor: 10.612
Authors: Tona M Gilmer; Louann Cable; Krystal Alligood; David Rusnak; Glenn Spehar; Kathleen T Gallagher; Ermias Woldu; H Luke Carter; Anne T Truesdale; Lisa Shewchuk; Edgar R Wood Journal: Cancer Res Date: 2008-01-15 Impact factor: 12.701
Authors: D W Rusnak; K J Alligood; R J Mullin; G M Spehar; C Arenas-Elliott; A-M Martin; Y Degenhardt; S K Rudolph; T F Haws; B L Hudson-Curtis; T M Gilmer Journal: Cell Prolif Date: 2007-08 Impact factor: 6.831
Authors: S John Weroha; Ann L Oberg; Katie L Allen Ziegler; Shaker R Dakhilm; Kendrith M Rowland; Lynn C Hartmann; Dennis F Moore; Gary L Keeney; Prema P Peethambaram; Paul Haluska Journal: Gynecol Oncol Date: 2011-04-22 Impact factor: 5.482
Authors: Christophe Antczak; Boyoung Wee; Constantin Radu; Bhavneet Bhinder; Eric C Holland; Hakim Djaballah Journal: Assay Drug Dev Technol Date: 2013-08-30 Impact factor: 1.738
Authors: Nancy U Lin; Wolfgang Eierman; Richard Greil; Mario Campone; Bella Kaufman; Klaudia Steplewski; Stephen R Lane; Denise Zembryki; Stephen D Rubin; Eric P Winer Journal: J Neurooncol Date: 2011-06-26 Impact factor: 4.130
Authors: Kathleen C Day; Guadalupe Lorenzatti Hiles; Molly Kozminsky; Scott J Dawsey; Alyssa Paul; Luke J Broses; Rajal Shah; Lakshmi P Kunja; Christopher Hall; Nallasivam Palanisamy; Stephanie Daignault-Newton; Layla El-Sawy; Steven James Wilson; Andrew Chou; Kathleen Woods Ignatoski; Evan Keller; Dafydd Thomas; Sunitha Nagrath; Todd Morgan; Mark L Day Journal: Cancer Res Date: 2016-10-28 Impact factor: 12.701
Authors: Angel M Carcaboso; Mohamed A Elmeliegy; Jun Shen; Stephen J Juel; Ziwei M Zhang; Christopher Calabrese; Lorraine Tracey; Christopher M Waters; Clinton F Stewart Journal: Cancer Res Date: 2010-05-11 Impact factor: 12.701